Frontiers in Oncology (Jul 2024)
The investigation of oncolytic viruses in the field of cancer therapy
- Zijun Yuan,
- Zijun Yuan,
- Yinping Zhang,
- Xiang Wang,
- Xingyue Wang,
- Siqi Ren,
- Xinyu He,
- Jiahong Su,
- Anfu Zheng,
- Sipeng Guo,
- Yu Chen,
- Yu Chen,
- Yu Chen,
- Shuai Deng,
- Shuai Deng,
- Shuai Deng,
- Xu Wu,
- Xu Wu,
- Xu Wu,
- Mingxing Li,
- Mingxing Li,
- Mingxing Li,
- Fukuan Du,
- Fukuan Du,
- Fukuan Du,
- Yueshui Zhao,
- Yueshui Zhao,
- Yueshui Zhao,
- Jing Shen,
- Jing Shen,
- Jing Shen,
- Zechen Wang,
- Zhangang Xiao,
- Zhangang Xiao,
- Zhangang Xiao,
- Zhangang Xiao,
- Zhangang Xiao
Affiliations
- Zijun Yuan
- Gulin Traditional Chinese Medicine Hospital, Luzhou, China
- Zijun Yuan
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Yinping Zhang
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Xiang Wang
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Xingyue Wang
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Siqi Ren
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Xinyu He
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Jiahong Su
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Anfu Zheng
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Sipeng Guo
- Research And Experiment Center, Sichuan College of Traditional Chinese Medicine, Mianyang, China
- Yu Chen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Yu Chen
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Yu Chen
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Shuai Deng
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Shuai Deng
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Shuai Deng
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Xu Wu
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Xu Wu
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Xu Wu
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Mingxing Li
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Mingxing Li
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Mingxing Li
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Fukuan Du
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Fukuan Du
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Fukuan Du
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Yueshui Zhao
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Yueshui Zhao
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Yueshui Zhao
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Jing Shen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Jing Shen
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Jing Shen
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Zechen Wang
- Gulin Traditional Chinese Medicine Hospital, Luzhou, China
- Zhangang Xiao
- Gulin Traditional Chinese Medicine Hospital, Luzhou, China
- Zhangang Xiao
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Zhangang Xiao
- Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Zhangang Xiao
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Zhangang Xiao
- Department of Pharmacology, School of Pharmacy, Sichuan College of Traditional Chinese Medicine, Mianyang, China
- DOI
- https://doi.org/10.3389/fonc.2024.1423143
- Journal volume & issue
-
Vol. 14
Abstract
Oncolytic viruses (OVs) have emerged as a potential strategy for tumor treatment due to their ability to selectively replicate in tumor cells, induce apoptosis, and stimulate immune responses. However, the therapeutic efficacy of single OVs is limited by the complexity and immunosuppressive nature of the tumor microenvironment (TME). To overcome these challenges, engineering OVs has become an important research direction. This review focuses on engineering methods and multi-modal combination therapies for OVs aimed at addressing delivery barriers, viral phagocytosis, and antiviral immunity in tumor therapy. The engineering approaches discussed include enhancing in vivo immune response, improving replication efficiency within the tumor cells, enhancing safety profiles, and improving targeting capabilities. In addition, this review describes the potential mechanisms of OVs combined with radiotherapy, chemotherapy, cell therapy and immune checkpoint inhibitors (ICIs), and summarizes the data of ongoing clinical trials. By continuously optimizing engineering strategies and combination therapy programs, we can achieve improved treatment outcomes and quality of life for cancer patients.
Keywords
